Brooks Laboratories Limited
NSE:BROOKS.NS
145.46 (INR) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 794.861 | 632.046 | 900.934 | 770.678 | 691.325 | 550.301 | 557.115 | 575.398 | 800.094 | 852.133 | 852.685 | 801.126 | 560.758 | 525.392 | 450.685 | 449.261 | 281.653 |
| Cost of Revenue
| 689.329 | 506.022 | 757.989 | 552.402 | 534.767 | 454.475 | 466.811 | 395.597 | 566.059 | 651.306 | 627.773 | 596.352 | 383.253 | 398.864 | 351.305 | 368.786 | 205.674 |
| Gross Profit
| 105.532 | 126.024 | 142.945 | 218.276 | 156.558 | 95.826 | 90.304 | 179.801 | 234.035 | 200.827 | 224.912 | 204.774 | 177.505 | 126.528 | 99.38 | 80.475 | 75.979 |
| Gross Profit Ratio
| 0.133 | 0.199 | 0.159 | 0.283 | 0.226 | 0.174 | 0.162 | 0.312 | 0.293 | 0.236 | 0.264 | 0.256 | 0.317 | 0.241 | 0.221 | 0.179 | 0.27 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 105.496 | 100.882 | 88.4 | 65.536 | 43.748 | 43.515 | 40.678 | 5.197 | 6.435 | 86.021 | 27.24 | 27.268 | 21.824 | 28.588 | 20.789 | 20.58 | 18.991 |
| Selling & Marketing Expenses
| 2.447 | 3.431 | 2.601 | 2.571 | 6.474 | 4.845 | 7.404 | 25.921 | 29.071 | 0.179 | 86.858 | 55.061 | 22.143 | 5.27 | 4.854 | 2.766 | 2.452 |
| SG&A
| 91.092 | 104.313 | 91.001 | 68.107 | 50.222 | 48.36 | 48.082 | 31.118 | 35.506 | 86.021 | 114.098 | 82.329 | 43.968 | 33.858 | 25.643 | 23.346 | 21.443 |
| Other Expenses
| 9.555 | 2.034 | 3.579 | 5.63 | 0.332 | 1.204 | 0.964 | 109.087 | 96.196 | 58.345 | 33.911 | 25.476 | 33.645 | 5.592 | 5.04 | 3.956 | 3.834 |
| Operating Expenses
| 91.092 | 460.475 | 361.046 | 284.278 | 249.002 | 216.88 | 243.645 | 140.205 | 131.702 | 144.366 | 148.009 | 107.805 | 77.612 | 39.45 | 30.682 | 27.302 | 25.277 |
| Operating Income
| 14.44 | -334.021 | -213.798 | -65.663 | -89.641 | -119.849 | -153.341 | 30.613 | 108.189 | 103.504 | 75.714 | 95.826 | 91.699 | 72.964 | 54.895 | 32.049 | 39.222 |
| Operating Income Ratio
| 0.018 | -0.528 | -0.237 | -0.085 | -0.13 | -0.218 | -0.275 | 0.053 | 0.135 | 0.121 | 0.089 | 0.12 | 0.164 | 0.139 | 0.122 | 0.071 | 0.139 |
| Total Other Income Expenses Net
| 1.106 | -49.761 | -25.179 | -24.27 | -45.496 | -29.63 | -22.001 | -8.983 | 5.856 | 47.043 | -1.189 | -1.144 | -8.194 | -14.113 | -13.802 | -21.124 | -11.48 |
| Income Before Tax
| 15.546 | -383.782 | -238.977 | -89.933 | -135.137 | -149.479 | -175.342 | 30.613 | 108.189 | 103.504 | 75.714 | 95.826 | 91.699 | 72.964 | 54.896 | 32.049 | 39.222 |
| Income Before Tax Ratio
| 0.02 | -0.607 | -0.265 | -0.117 | -0.195 | -0.272 | -0.315 | 0.053 | 0.135 | 0.121 | 0.089 | 0.12 | 0.164 | 0.139 | 0.122 | 0.071 | 0.139 |
| Income Tax Expense
| 0.259 | -73.24 | -45.851 | 103.822 | 108.623 | -1.425 | -37.214 | 11.048 | 1.855 | 8.832 | 3.319 | 24.388 | 3.34 | 3.015 | 3.176 | 2.408 | 6.952 |
| Net Income
| -195.919 | -209.002 | -193.126 | -193.755 | -243.76 | -148.054 | -138.128 | 19.565 | 106.334 | 94.672 | 72.394 | 71.439 | 88.359 | 68.882 | 51.72 | 29.641 | 32.27 |
| Net Income Ratio
| -0.246 | -0.331 | -0.214 | -0.251 | -0.353 | -0.269 | -0.248 | 0.034 | 0.133 | 0.111 | 0.085 | 0.089 | 0.158 | 0.131 | 0.115 | 0.066 | 0.115 |
| EPS
| -7.67 | -8.38 | -7.74 | -7.77 | -13.71 | -7.37 | -7.12 | 0.86 | 5.48 | 4.88 | 3.73 | 3.68 | 4.55 | 5.81 | 9.27 | 9.56 | 2.74 |
| EPS Diluted
| -7.67 | -8.38 | -7.74 | -7.77 | -13.71 | -7.37 | -7.12 | 0.86 | 5.48 | 4.88 | 3.73 | 3.68 | 4.55 | 5.81 | 4.4 | 9.56 | 2.74 |
| EBITDA
| 32.173 | -295.249 | -140.544 | 12.706 | -24.09 | -53.754 | -86.848 | 56.101 | 126.691 | 88.802 | 85.221 | 105.109 | 106.455 | 93.191 | 73.883 | 57.544 | 54.581 |
| EBITDA Ratio
| 0.04 | -0.467 | -0.156 | 0.016 | -0.035 | -0.098 | -0.156 | 0.097 | 0.158 | 0.104 | 0.1 | 0.131 | 0.19 | 0.177 | 0.164 | 0.128 | 0.194 |